Banco Bilbao Vizcaya Argentaria S.A. Has $704,000 Holdings in DexCom, Inc. $DXCM

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. reduced its holdings in DexCom, Inc. by 50.9%, now owning 10,326 shares valued at $704,000.
• Equities analysts have given DexCom a consensus rating of "Moderate Buy" with a target price averaging $99.89.
• DexCom reported a quarterly earnings per share (EPS) of $0.48, exceeding estimates, with revenue increasing by 15.2% year-over-year to $1.16 billion.

Banco Bilbao Vizcaya Argentaria S.A. lessened its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 50.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,326 shares of the medical device company's stock after selling 10,688 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in DexCom were worth $704,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Golden State Wealth Management LLC increased its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in DexCom during the first quarter valued at approximately $27,000. Optiver Holding B.V. bought a new stake in DexCom in the fourth quarter valued at approximately $33,000. Heck Capital Advisors LLC bought a new stake in DexCom in the fourth quarter valued at approximately $38,000. Finally, Alpine Bank Wealth Management acquired a new stake in DexCom in the first quarter worth $40,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Robert W. Baird decreased their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Raymond James Financial boosted their target price on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Piper Sandler raised their price target on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. UBS Group lifted their price objective on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Finally, Citigroup reissued a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.89.

DexCom Stock Performance

DXCM opened at $82.26 on Friday. The company has a market capitalization of $32.26 billion, a price-to-earnings ratio of 57.13, a P/E/G ratio of 1.72 and a beta of 1.43. The business's 50-day moving average price is $82.81 and its two-hundred day moving average price is $79.83. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the company earned $0.43 earnings per share. DexCom's quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president owned 109,621 shares of the company's stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,906 shares of company stock valued at $1,832,451 over the last quarter. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.